Amicus Therapeutics to Present at 32nd Annual J.P. Morgan Healthcare Conference

Amicus Therapeutics to Present at 32nd Annual J.P. Morgan Healthcare
Conference

CRANBURY, N.J., Jan. 10, 2014 (GLOBE NEWSWIRE) -- Amicus Therapeutics
(Nasdaq:FOLD), a biopharmaceutical company at the forefront of developing
therapies for rare and orphan diseases, today announced that John F. Crowley,
Chairman and Chief Executive Officer, will present the Company's full-year
2014 strategic outlook at the 32^nd Annual J.P. Morgan Healthcare Conference
on Thursday, January 16, 2014 at 11:30 a.m. PT (2:30 p.m. ET).

A live webcast of the presentation can be accessed through the Investors
section of the Amicus Therapeutics corporate web site at
http://ir.amicustherapeutics.com/events.cfm, and will be archived for 90 days.


About Amicus Therapeutics

Amicus Therapeutics (Nasdaq:FOLD) is a biopharmaceutical company at the
forefront of therapies for rare and orphan diseases. The Company is developing
novel, first-in-class treatments for a broad range of human genetic diseases,
with a focus on delivering new benefits to individuals with lysosomal storage
diseases. Amicus' lead programs include the small molecule pharmacological
chaperones migalastat HCl as a monotherapy and in combination with enzyme
replacement therapy (ERT) for Fabry disease; and AT2220 (duvoglustat HCl) in
combination with ERT for Pompe disease.

FOLD-G

CONTACT: Amicus Therapeutics
         Sara Pellegrino
         (609) 662-5044
         spellegrino@amicusrx.com
 
Press spacebar to pause and continue. Press esc to stop.